Comparative Pharmacology
Head-to-head clinical analysis: BRENZAVVY versus EMPAGLIFLOZIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRENZAVVY versus EMPAGLIFLOZIN.
BRENZAVVY vs EMPAGLIFLOZIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brenzavvy (bexagliflozin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. It inhibits SGLT2 in the proximal renal tubule, reducing glucose reabsorption and increasing urinary glucose excretion, thereby lowering blood glucose levels. It also promotes osmotic diuresis and may improve cardiovascular and renal outcomes through hemodynamic and metabolic effects.
Sodium-glucose cotransporter 2 (SGLT2) inhibitor; reduces renal glucose reabsorption, increasing urinary glucose excretion.
Recommended dose: 1 tablet (200 mg finerenone) orally once daily.
10 mg orally once daily, with or without food; may increase to 25 mg once daily if eGFR ≥60 mL/min/1.73 m² and additional glycemic control needed.
None Documented
None Documented
Clinical Note
moderateEmpagliflozin + Gatifloxacin
"Empagliflozin may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateEmpagliflozin + Rosoxacin
"Empagliflozin may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateEmpagliflozin + Levofloxacin
"Empagliflozin may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateEmpagliflozin + Trovafloxacin
"Empagliflozin may increase the hypoglycemic activities of Trovafloxacin."
The terminal elimination half-life is approximately 12-15 hours in patients with normal renal function, supporting once-daily dosing.
Terminal elimination half-life is approximately 12.4 hours (range 10-18 h) in patients with T2DM; supports once-daily dosing.
Approximately 65% of the dose is excreted renally as unchanged drug, and about 35% is eliminated via biliary/fecal routes as metabolites.
Renal (54% as unchanged drug) and fecal (41% as unchanged drug or metabolites); biliary excretion is minimal.
Category C
Category C
SGLT2 Inhibitor
SGLT2 Inhibitor